Govt might reduce age gap between Covishield doses for 45 and above: Report

The National Technical Advisory Group on Immunisation in India (NTAGI) has indicated it will decide on the interval at its next meeting

coronavirus, covid-19, vaccine, vaccination
A student receives a dose of Covid-19 vaccine at the Maharani Sundarshan College in Bikaner on Wednesday, August 4, 2021. (PTI Photo)
BS Web Team New Delhi
1 min read Last Updated : Aug 05 2021 | 10:49 AM IST
The government might soon reduce the gap between the two doses of Covishield for those above 45 years as vaccine supply improves and criticism mounts over a lack of scientific reasoning behind the current 12-16 weeks interval between the two jabs, says a report in Mint.

The National Technical Advisory Group on Immunisation in India (NTAGI) has indicated it will decide on the interval at its next meeting, expected to be held in the next fortnight or a month, once it has reviewed the scientific data collected by it.

India had started with an interval of four weeks, but later extended the gap to 4-8 weeks based on available evidence. Later, it further increased the interval to 12-14 weeks.

One subscription. Two world-class reads.

Already subscribed? Log in

Subscribe to read the full story →
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

Topics :CoronavirusCoronavirus VaccineVaccination

Next Story